<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215917</url>
  </required_header>
  <id_info>
    <org_study_id>lichtenberg1CTIL</org_study_id>
    <nct_id>NCT00215917</nct_id>
  </id_info>
  <brief_title>D-Serine Monotherapy for Schizophrenia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herzog Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herzog Hospital</source>
  <brief_summary>
    <textblock>
      N-methyl-D-aspartate receptor (NMDAR) agonist, added to classical or atypical antipsychotic
      medication, has reduced negative, depressive, and cognitive symptomatology. We will be
      investigating the effect of D-serine, (DSR), a selective and potent NMDAR agonist, as
      monotherapy for treatment resistant schizophrenics.

      40 subjects on stable doses of risperidone will be randomized under double-blind conditions
      into a treatment group, which will receive D-serine 2100 mg, or a control group, which will
      continue to receive risperidone. Treatment will continue for 14 weeks.

      Symptoms and side effects will be rated biweekly with the CGI, PANSS, BPRS, SAS, AIMS, and
      UKU. Before and after the trial subjects will undergo neuropsychological assessments.
      Baseline and post-trial levels of amino acids relevant to glutamatergic neurotransmission
      (glutamate, glutamine, aspartate, glycine, serine, alanine) will be assessed.

      The primary outcome measures of the study will be the PANSS total scores and the positive and
      negative symptom cluster scores.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-serine 2100 mg daily</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. DSM-IV criteria for chronic schizophrenia

          2. Treatment resistant

          3. aged 18-70

          4. Two months on stable risperidone dose

          5. PANSS positive symptom cluster score &gt;20

          6. PANSS negative symptom cluster score &gt;22

        Exclusion Criteria:

          1. Substance abuse

          2. Concurrent DSM IV axis I disorder

          3. Serious medical disorder

          4. Concurrent drug therapy that can obscure the effect of risperidone or DSR.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pesach Lichtenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzog Hospital, and Hadassah Medical School--the Hebrew University of Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pesach Lichtenberg, M.D.</last_name>
    <phone>972-2-6221154</phone>
    <email>licht@cc.huji.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herzog Hospital, Department of Psychiatry</name>
      <address>
        <city>Jerusalem</city>
        <zip>91351</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pesach Lichtenberg, M.D.</last_name>
      <phone>972-2-5316929</phone>
      <email>licht@cc.huji.ac.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2005</study_first_submitted>
  <study_first_submitted_qc>September 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>May 1, 2006</last_update_submitted>
  <last_update_submitted_qc>May 1, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2006</last_update_posted>
  <keyword>Schizophrenia</keyword>
  <keyword>NMDA</keyword>
  <keyword>D-serine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

